{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:30:07Z","timestamp":1768401007836,"version":"3.49.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,10]],"date-time":"2013-10-10T00:00:00Z","timestamp":1381363200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00198-013-2521-4","type":"journal-article","created":{"date-parts":[[2013,10,10]],"date-time":"2013-10-10T17:48:37Z","timestamp":1381427317000},"page":"325-337","source":"Crossref","is-referenced-by-count":27,"title":["Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm"],"prefix":"10.1007","volume":"25","author":[{"given":"K.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Svedbom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sutradhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,10]]},"reference":[{"issue":"Suppl 2","key":"2521_CR1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/PL00004156","volume":"9","author":"C Cooper","year":"1999","unstructured":"Cooper C (1999) Epidemiology of osteoporosis. Osteoporos Int 9(Suppl 2):S2\u2013S8","journal-title":"Osteoporos Int"},{"key":"2521_CR2","doi-asserted-by":"crossref","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Joonsson B, Kanis J (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. Archives of Osteoporosis (in press)","DOI":"10.1007\/s11657-013-0136-1"},{"key":"2521_CR3","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1359\/jbmr.2003.18.11.1947","volume":"18","author":"KL Stone","year":"2003","unstructured":"Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, Nevitt MC, Cummings SR (2003) BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res 18:1947\u20131954. doi: 10.1359\/jbmr.2003.18.11.1947","journal-title":"J Bone Miner Res"},{"key":"2521_CR4","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00198-005-1997-y","volume":"16","author":"JA Pasco","year":"2005","unstructured":"Pasco JA, Sanders KM, Hoekstra FM, Henry MJ, Nicholson GC, Kotowicz MA (2005) The human cost of fracture. Osteoporos Int 16:2046\u20132052. doi: 10.1007\/s00198-005-1997-y","journal-title":"Osteoporos Int"},{"key":"2521_CR5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.7326\/0003-4819-128-10-199805150-00001","volume":"128","author":"MC Nevitt","year":"1998","unstructured":"Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793\u2013800","journal-title":"Ann Intern Med"},{"key":"2521_CR6","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00198-004-1627-0","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA (2004) An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 15:897\u2013902","journal-title":"Osteoporos Int"},{"key":"2521_CR7","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733","journal-title":"Osteoporos Int"},{"key":"2521_CR8","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","volume":"337","author":"PD Delmas","year":"1997","unstructured":"Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641\u20131647","journal-title":"N Engl J Med"},{"key":"2521_CR9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Jama 282:637\u2013645","journal-title":"Jama"},{"key":"2521_CR10","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","volume":"23","author":"SL Silverman","year":"2008","unstructured":"Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial *. J Bone Miner Res 23:1923\u20131934","journal-title":"J Bone Miner Res"},{"key":"2521_CR11","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","volume":"44","author":"JA Kanis","year":"2009","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049\u20131054","journal-title":"Bone"},{"key":"2521_CR12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00198-011-1691-1","volume":"23","author":"SL Silverman","year":"2011","unstructured":"Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjaerg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD (2011) Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 23:351\u2013363. doi: 10.1007\/s00198-011-1691-1","journal-title":"Osteoporos Int"},{"key":"2521_CR13","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/jbmr.12","volume":"25","author":"FA Tremollieres","year":"2010","unstructured":"Tremollieres FA, Pouilles JM, Drewniak N, Laparra J, Ribot CA, Dargent-Molina P (2010) Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool. J Bone Miner Res 25:1002\u20131009. doi: 10.1002\/jbmr.12","journal-title":"J Bone Miner Res"},{"key":"2521_CR14","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00198-011-1713-z","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj FG, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395\u20132411","journal-title":"Osteoporos Int"},{"key":"2521_CR15","unstructured":"Committee for Medicinal Products for Human Use (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP\/EWP\/552\/95Rev.2. CHMP, London"},{"key":"2521_CR16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bone.2010.06.009","volume":"47","author":"JA Kanis","year":"2010","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2010) A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. BONE 47:729\u2013735","journal-title":"BONE"},{"key":"2521_CR17","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s00198-010-1474-0","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R)). Osteoporos Int 22:2347\u20132355. doi: 10.1007\/s00198-010-1474-0","journal-title":"Osteoporos Int"},{"key":"2521_CR18","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-008-0786-9","volume":"20","author":"EV McCloskey","year":"2009","unstructured":"McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, Jalava T, Kanis JA (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy\u2014additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811\u2013817","journal-title":"Osteoporos Int"},{"key":"2521_CR19","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/jbmr.1606","volume":"27","author":"EV McCloskey","year":"2012","unstructured":"McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 27:1480\u20131486. doi: 10.1002\/jbmr.1606","journal-title":"J Bone Miner Res"},{"key":"2521_CR20","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00198-010-1291-5","volume":"22","author":"F Borgstrom","year":"2010","unstructured":"Borgstrom F, Strom O, Kleman M, McCloskey E, Johansson H, Oden A, Kanis JA (2010) Cost-effectiveness of bazedoxifene incorporating the FRAX(R) algorithm in a European perspective. Osteoporos Int 22:955\u2013965. doi: 10.1007\/s00198-010-1291-5","journal-title":"Osteoporos Int"},{"key":"2521_CR21","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","volume":"38","author":"KF Huybrechts","year":"2006","unstructured":"Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. BONE 38:922\u2013928","journal-title":"BONE"},{"key":"2521_CR22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00198-006-0294-8","volume":"18","author":"E Seeman","year":"2007","unstructured":"Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, Jonsson B, Pols H, Cramer JA (2007) Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int 18:711\u2013719. doi: 10.1007\/s00198-006-0294-8","journal-title":"Osteoporos Int"},{"key":"2521_CR23","unstructured":"The Belgian Health Care Knowledge Centre (2008) Guidelines for pharmacoeconomic evaluations in Belgium: KCE reports 78C. The Belgian Health Care Knowledge Centre (KCE), Brussels"},{"key":"2521_CR24","unstructured":"NICE (2008) Guide to the methods of technology appraisal. http:\/\/www.nice.org\/uk\/media\/B52\/A7\/TAMethodsGuideUpdatedJune2008.pdf . Accessed June 2008"},{"key":"2521_CR25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","volume":"24","author":"BJ Lopez","year":"2010","unstructured":"Lopez BJ, Oliva J, Antonanzas F, Garcia-Altes A, Gisbert R, Mar J, Puig-Junoy J (2010) A proposed guideline for economic evaluation of health technologies. Gac Sanit 24:154\u2013170","journal-title":"Gac Sanit"},{"key":"2521_CR26","unstructured":"Health Information and Quality Authority (2010) Guidelines for the economic evaluation of health technologies in Ireland. Health Information and Quality Authority, Cork"},{"key":"2521_CR27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/009286150103500122","volume":"35","author":"S Capri","year":"2001","unstructured":"Capri S, Ceci A, Terranova L, Merlo F, Mantovani L (2001) Guidelines for economics evaluations in Italy: recommendations from the Italian group of pharmacoeconomic stuides. Drug Inf J 35:189\u2013201","journal-title":"Drug Inf J"},{"key":"2521_CR28","unstructured":"Sorenson C, Drummond M, Kanavos P (2008) Ensuring value for money in health care: the role of health technology assessment in the European Union. European Observatory on Health Systems and Policies. Observatory Studies Series No.11"},{"key":"2521_CR29","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s001980200106","volume":"13","author":"JA Kanis","year":"2002","unstructured":"Kanis JA, Jonsson B (2002) Economic evaluation of interventions for osteoporosis. Osteoporos Int 13:765\u2013767","journal-title":"Osteoporos Int"},{"key":"2521_CR30","unstructured":"Cox DR, Oakes D (1984) Analysis of survival data. Monographs on statistics and applied probability 21. Chapman & Hall, London"},{"key":"2521_CR31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00198-004-1688-0","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16:15\u201325","journal-title":"Osteoporos Int"},{"key":"2521_CR32","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"2521_CR33","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118\u20134124","journal-title":"J Clin Endocrinol Metab"},{"key":"2521_CR34","unstructured":"EMEA (2009). Committe for medicinal products for human use\u2014summary of positive opinion for Conbriza. EMEA, London, 19 February 2009"},{"key":"2521_CR35","unstructured":"Federaal Ministerie van Sociale Zaken, Volksgezondheid en Leefmilieu. Bestuur van de gezondheidszorgen. Commissie voor toezicht op en evaluatie van statistische gegevens die verband houden met de medische activiteiten in de ziekenhuizen. Rijksadministratif centrum. Brussel. Upon written request"},{"key":"2521_CR36","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s00198-009-0922-1","volume":"20","author":"MK Dodds","year":"2009","unstructured":"Dodds MK, Codd MB, Looney A, Mulhall KJ (2009) Incidence of hip fracture in the Republic of Ireland and future projections: a population-based study. Osteoporos Int 20:2105\u20132110. doi: 10.1007\/s00198-009-0922-1","journal-title":"Osteoporos Int"},{"key":"2521_CR37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s001980170112","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417\u2013427","journal-title":"Osteoporos Int"},{"key":"2521_CR38","volume-title":"Assessment of osteoporosis at the primary health-care level. Technical report","author":"J Kanis","year":"2008","unstructured":"Kanis J (2008) Assessment of osteoporosis at the primary health-care level. Technical report. WHO Collaborating Centre, University of Sheffield, , UK"},{"key":"2521_CR39","unstructured":"IARC (2008). GLOBOCAN 2008. Cancer incidence, mortality and prevalence worldwide in 2008. International Agency for Research on Cancer, Lyon. http:\/\/globocan.iarc.fr\/"},{"key":"2521_CR40","unstructured":"Wilmoth JR, Shkolnikov V (2012). The human mortality database (HMD). Online source http:\/\/www.mortality.org\/"},{"key":"2521_CR41","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s001980050105","volume":"8","author":"A Oden","year":"1998","unstructured":"Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8:599\u2013603","journal-title":"Osteoporos Int"},{"key":"2521_CR42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00198-003-1490-4","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, de Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38\u201342","journal-title":"Osteoporos Int"},{"key":"2521_CR43","doi-asserted-by":"crossref","unstructured":"Poor G, Atkinson EJ, O'Fallon WM, Melton LJ III (1995) Determinants of reduced survival following hip fractures in men. Clin Orthop 319:260\u2013265.","DOI":"10.1097\/00003086-199510000-00028"},{"key":"2521_CR44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Oden A, Johnell O, de Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108\u2013112","journal-title":"Osteoporos Int"},{"key":"2521_CR45","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0033-3506(05)80614-6","volume":"105","author":"MJ Parker","year":"1991","unstructured":"Parker MJ, Anand JK (1991) What is the true mortality of hip fractures? Public Health 105:443\u2013446","journal-title":"Public Health"},{"key":"2521_CR46","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O, de Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. BONE 32:468\u2013473","journal-title":"BONE"},{"key":"2521_CR47","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00198-007-0349-5","volume":"18","author":"O Strom","year":"2007","unstructured":"Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries\u2014an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047\u20131061","journal-title":"Osteoporos Int"},{"key":"2521_CR48","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1007\/s00198-006-0094-1","volume":"17","author":"F Borgstrom","year":"2006","unstructured":"Borgstrom F, Carlsson A, Sintonen H, Boonen S, Haentjens P, Burge R, Johnell O, Jonsson B, Kanis JA (2006) The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 17:996\u20131007","journal-title":"Osteoporos Int"},{"key":"2521_CR49","unstructured":"NICE (2008) Osteoporosis\u2014secondary prevention including strontium ranelate: appraisal consultation document. www.nice.org.uk"},{"key":"2521_CR50","first-page":"I22","volume":"107","author":"C Kearon","year":"2003","unstructured":"Kearon C (2003) Natural history of venous thromboembolism. Circulation 107:I22\u2013I30","journal-title":"Circulation"},{"key":"2521_CR51","first-page":"213","volume":"101","author":"A Azhar","year":"2008","unstructured":"Azhar A, Lim C, Kelly E, O'Rourke K, Dudeney S, Hurson B, Quinlan W (2008) Cost induced by hip fractures. Ir Med J 101:213\u2013215","journal-title":"Ir Med J"},{"key":"2521_CR52","doi-asserted-by":"crossref","unstructured":"Bouee S, Lafuma A, Fagnani F, Meunier PJ, Reginster JY (2006) Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries. Rheumatol Int 26: 1063\u20131072. doi. 10.1007\/s00296-006-0180-x","DOI":"10.1007\/s00296-006-0180-x"},{"key":"2521_CR53","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/03009749609103742","volume":"103","author":"B Jonsson","year":"1996","unstructured":"Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30\u201338","journal-title":"Scand J Rheumatol Suppl"},{"key":"2521_CR54","unstructured":"Kanis J (2001). Epidemiology and costs of fractures in the UK\u2014background document for male osteoporosis model. Personal communication 2001"},{"key":"2521_CR55","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00198-006-0193-z","volume":"17","author":"F Borgstrom","year":"2006","unstructured":"Borgstrom F, Jonsson B, Strom O, Kanis JA (2006) An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 17:1781\u20131793","journal-title":"Osteoporos Int"},{"key":"2521_CR56","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10198-010-0237-3","volume":"12","author":"S Broekx","year":"2011","unstructured":"Broekx S, Den HE, Torfs R, Remacle A, Mertens R, D'Hooghe T, Neven P, Christiaens MR, Simoens S (2011) The costs of breast cancer prior to and following diagnosis. Eur J Health Econ 12:311\u2013317","journal-title":"Eur J Health Econ"},{"key":"2521_CR57","doi-asserted-by":"crossref","unstructured":"The World Bank (2010). Global purchasing power parities and real expenditures. The World Bank Database 2010. http:\/\/data.worldbank.org\/ . Accessed Dec 2011","DOI":"10.1596\/978-0-8213-8376-6"},{"key":"2521_CR58","unstructured":"Statistics Belgium (2012) www.statbel.fgov.be . Accessed Oct 2012"},{"key":"2521_CR59","unstructured":"Stevenson M, Davis S (2006). Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide. NICE, London"},{"key":"2521_CR60","first-page":"1","volume":"24","author":"JG Brecht","year":"2004","unstructured":"Brecht JG, Kruse HP, Mohrke W, Oestreich A, Huppertz E (2004) Health\u2013economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res 24:1\u201310","journal-title":"Int J Clin Pharmacol Res"},{"key":"2521_CR61","doi-asserted-by":"crossref","unstructured":"Visentin P, Ciravegna R, Fabris F (1997) Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 26:185\u2013192. doi:S0378512296010997","DOI":"10.1016\/S0378-5122(96)01099-7"},{"key":"2521_CR62","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00198-005-0015-8","volume":"17","author":"F Borgstrom","year":"2006","unstructured":"Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjo K, Thorngren KG, Sernbo I, Rehnberg C, Jonsson B (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17:637\u2013650. doi: 10.1007\/s00198-010-1291-5","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"2521_CR63","first-page":"57","volume":"17","author":"N Zethraeus","year":"2006","unstructured":"Zethraeus N, Strom O, Borgstrom F (2006) What is the risk of institutionalization after hip fracture? Osteoporos Int 17(Suppl 1):57\u201358","journal-title":"Osteoporos Int"},{"key":"2521_CR64","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1046\/j.1538-7836.2003.00396.x","volume":"1","author":"A Gordois","year":"2003","unstructured":"Gordois A, Posnett J, Borris L, Bossuyt P, Jonsson B, Levy E, de Pouvourville G (2003) The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J Thromb Haemost 1:2167\u20132174","journal-title":"J Thromb Haemost"},{"key":"2521_CR65","unstructured":"The National Board of Health and Welfare in Sweden (2010). http:\/\/www.socialstyrelsen.se . Accessed Dec 2010"},{"key":"2521_CR66","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1017\/S0266462310000358","volume":"26","author":"P Gillespie","year":"2010","unstructured":"Gillespie P, O'Shea E, Murphy AW, Byrne MC, Byrne M, Smith SM, Cupples ME (2010) The cost-effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease. Int J Technol Assess Health Care 26:263\u2013271","journal-title":"Int J Technol Assess Health Care"},{"key":"2521_CR67","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s001980070102","volume":"11","author":"P Autier","year":"2000","unstructured":"Autier P, Haentjens P, Bentin J, Baillon JM, Grivegnee AR, Closon MC, Boonen S (2000) Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 11:373\u2013380","journal-title":"Osteoporos Int"},{"issue":"Suppl 2","key":"2521_CR68","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1007\/s10198-006-0381-y","volume":"7","author":"G Kobelt","year":"2006","unstructured":"Kobelt G, Berg J, Lindgren P, Izquierdo G, Sanchez-Solino O, Perez-Miranda J, Casado MA (2006) Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ 7(Suppl 2):S65\u2013S74. doi: 10.1007\/s10198-006-0381-y","journal-title":"Eur J Health Econ"},{"key":"2521_CR69","unstructured":"Stadsledningskontoret. Stockholms stads budgetavr\u00e4kning. 2003"},{"key":"2521_CR70","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1023\/A:1013171831202","volume":"10","author":"K Burstrom","year":"2001","unstructured":"Burstrom K, Johannesson M, Diderichsen F (2001) Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 10:621\u2013635","journal-title":"Qual Life Res"},{"key":"2521_CR71","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/bmj.316.7133.736","volume":"316","author":"P Kind","year":"1998","unstructured":"Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. Br Med J 316:736\u2013741","journal-title":"Br Med J"},{"key":"2521_CR72","first-page":"1","volume":"8","author":"NO Foundation","year":"1998","unstructured":"Foundation NO (1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoorosis Int 8:1\u201388","journal-title":"Osteoorosis Int"},{"key":"2521_CR73","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eurpsy.2006.10.006","volume":"22","author":"P Sobocki","year":"2007","unstructured":"Sobocki P, Lekander I, Borgstrom F, Strom O, Runeson B (2007) The economic burden of depression in Sweden from 1997 to 2005. Eur Psychiatry 22:146\u2013152","journal-title":"Eur Psychiatry"},{"key":"2521_CR74","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1017\/S0266462305050609","volume":"21","author":"N Zethraeus","year":"2005","unstructured":"Zethraeus N, Borgstrom F, Jonsson B, Kanis J (2005) Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial. Int J Technol Assess Health Care 21:433\u2013441","journal-title":"Int J Technol Assess Health Care"},{"key":"2521_CR75","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/17453670710015094","volume":"79","author":"O Str\u00f6m","year":"2008","unstructured":"Str\u00f6m O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Ceder L, Thorngren KG, Sernbo I, Jonsson B (2008) Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 79:269\u2013280. doi: 10.1080\/17453670710015094","journal-title":"Acta Orthop"},{"key":"2521_CR76","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","volume":"18","author":"JA Kanis","year":"2007","unstructured":"Kanis JA, Oden A, Johnell O, Johansson H, de Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Gluer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ III, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033\u20131046","journal-title":"Osteoporos Int"},{"key":"2521_CR77","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00198-009-0989-8","volume":"21","author":"F Borgstrom","year":"2010","unstructured":"Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495\u2013505. doi: 10.1007\/s00198-009-0989-8","journal-title":"Osteoporos Int"},{"key":"2521_CR78","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-009-0971-5","volume":"21","author":"F Borgstrom","year":"2010","unstructured":"Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey E, Kanis JA (2010) The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int 21:339\u2013349. doi: 10.1007\/s00198-009-0971-5","journal-title":"Osteoporos Int"},{"key":"2521_CR79","unstructured":"Str\u00f6m O, Borgstrom F, Kleman M, McCloskey E, Od\u00e9n A, Johansson H, Kanis J (2010). FRAX\u00ae and its applications in health economics. Cost-effectiveness and intervention thresholds. BONE 47:430\u2013437"},{"key":"2521_CR80","doi-asserted-by":"crossref","unstructured":"Hiligsmann M, Sedrine WB, Reginster JY (2012). Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. J Bone Miner Res. doi: 10.1002\/jbmr.1819","DOI":"10.1002\/jbmr.1819"},{"key":"2521_CR81","unstructured":"Darba J, Perez N, Kaskens L, Racketa J, Rejas J (2011). A cost-effectiveness model of bazedoxifene versus raloxifene for the prevention of fractures in Spanish postmenopausal women. European Congress on Osteoporosis and Osteoarthritis (ECCEO11-IOF) 2011, Valencia (Spain)"},{"key":"2521_CR82","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","volume":"39","author":"TP Staa van","year":"2000","unstructured":"van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39:1383\u20131389","journal-title":"Rheumatology (Oxford)"},{"key":"2521_CR83","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00198-004-1734-y","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johansson H, Johnell O, Oden A, de Laet C, Eisman JA, Pols H, Tenenhouse A (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737\u2013742","journal-title":"Osteoporos Int"},{"key":"2521_CR84","unstructured":"National Services Scotland (2009). The patient journey post hip fracture: what constitutes rehabilitation?\u2014A report from the Scottish hip fracture audit. Scottish Hip Fracture Audit 2009. http:\/\/www.shfa.scot.nhs.uk\/"},{"key":"2521_CR85","doi-asserted-by":"crossref","unstructured":"Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125\u2013137. doi: 10.1056\/NEJMoa062462","DOI":"10.1056\/NEJMoa062462"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-013-2521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-013-2521-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-013-2521-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T18:25:26Z","timestamp":1646763926000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-013-2521-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,10]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["2521"],"URL":"https:\/\/doi.org\/10.1007\/s00198-013-2521-4","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,10]]}}}